This document is an excerpt from the EUR-Lex website
Document 62020TA0215
Case T-215/20: Judgment of the General Court of 16 June 2021 — Fidia farmaceutici v EUIPO — Ioulia and Irene Tseti Pharmaceutical Laboratories (HYAL) (EU trade mark — Invalidity proceedings — EU word mark HYAL — Article 51(1)(a) of Regulation (EC) No 40/94 (now Article 59(1)(a) of Regulation (EU) 2017/1001) — Absolute ground for refusal — Article 7(1)(c) of Regulation No 40/94 (now Article 7(1)(c) of Regulation 2017/1001) — Right to be heard — Audi alteram partem rule — Obligation to state reasons — Sound administration and equal treatment — Article 165(1) of Regulation 2017/1001)
Case T-215/20: Judgment of the General Court of 16 June 2021 — Fidia farmaceutici v EUIPO — Ioulia and Irene Tseti Pharmaceutical Laboratories (HYAL) (EU trade mark — Invalidity proceedings — EU word mark HYAL — Article 51(1)(a) of Regulation (EC) No 40/94 (now Article 59(1)(a) of Regulation (EU) 2017/1001) — Absolute ground for refusal — Article 7(1)(c) of Regulation No 40/94 (now Article 7(1)(c) of Regulation 2017/1001) — Right to be heard — Audi alteram partem rule — Obligation to state reasons — Sound administration and equal treatment — Article 165(1) of Regulation 2017/1001)
Case T-215/20: Judgment of the General Court of 16 June 2021 — Fidia farmaceutici v EUIPO — Ioulia and Irene Tseti Pharmaceutical Laboratories (HYAL) (EU trade mark — Invalidity proceedings — EU word mark HYAL — Article 51(1)(a) of Regulation (EC) No 40/94 (now Article 59(1)(a) of Regulation (EU) 2017/1001) — Absolute ground for refusal — Article 7(1)(c) of Regulation No 40/94 (now Article 7(1)(c) of Regulation 2017/1001) — Right to be heard — Audi alteram partem rule — Obligation to state reasons — Sound administration and equal treatment — Article 165(1) of Regulation 2017/1001)
OJ C 310, 2.8.2021, p. 24–25
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
- Date of document:
- 16/06/2021
- Date lodged:
- 21/04/2020
- Author:
- General Court
- Form:
- Judicial information
- Authentic language:
- English
- Type of procedure:
- Action for annulment - unfounded
- Defendant:
- European Union Intellectual Property Office
- Link
- Select all documents mentioning this document
- Case affecting:
-
- Related EU case-law document 62020TJ0215
- Instruments cited in case law:
- Link
|
2.8.2021 |
EN |
Official Journal of the European Union |
C 310/24 |
Judgment of the General Court of 16 June 2021 — Fidia farmaceutici v EUIPO — Ioulia and Irene Tseti Pharmaceutical Laboratories (HYAL)
(Case T-215/20) (1)
(EU trade mark - Invalidity proceedings - EU word mark HYAL - Article 51(1)(a) of Regulation (EC) No 40/94 (now Article 59(1)(a) of Regulation (EU) 2017/1001) - Absolute ground for refusal - Article 7(1)(c) of Regulation No 40/94 (now Article 7(1)(c) of Regulation 2017/1001) - Right to be heard - Audi alteram partem rule - Obligation to state reasons - Sound administration and equal treatment - Article 165(1) of Regulation 2017/1001)
(2021/C 310/30)
Language of the case: English
Parties
Applicant: Fidia farmaceutici SpA (Abano Terme, Italy) (represented by: R. Kunz-Hallstein and H.P. Kunz-Hallstein, lawyers)
Defendant: European Union Intellectual Property Office (represented by: E. Sliwinska, V. Ruzek and H. O’Neill, acting as Agents)
Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Ioulia and Irene Tseti Pharmaceutical Laboratories SA (Athens, Greece) (represented by: C. Chrysanthis, P.-V. Chardalia and A. Vasilogamvrou, lawyers)
Re:
Action brought against the decision of the Fifth Board of Appeal of EUIPO of 24 January 2020 (Case R 613/2019-5), relating to invalidity proceedings between Ioulia and Irene Tseti Pharmaceutical Laboratories and Fidia farmaceutici.
Operative part of the judgment
The Court:
|
1. |
Dismisses the action; |
|
2. |
Orders Fidia farmaceutici SpA to pay the costs. |
